Real Patient Outcomes: The AI-Native Edge for Cardiac Investment

The promise of artificial intelligence in healthcare is vast, yet its true impact hinges on a fundamental distinction: the data upon which it is built. While generalist AI models captivate with their broad capabilities, their application in clinical contexts often falters due to a critical absence, real patient outcomes data. This gap defines the chasm between AI applied to health and truly AI-native health platforms.

The Allure and a Hard Limit: General AI’s Entry into Healthcare

The current landscape is awash with enthusiasm for large language models (LLMs) and general AI being applied to healthcare. Models developed by entities like Google Health AI demonstrate impressive capabilities in processing and summarizing vast amounts of public medical literature, offering rapid access to information that once required extensive manual research. ChatGPT, for instance, has garnered attention for its ability to pass medical licensing exams, showcasing its prowess in pattern matching across publicly available textual data. However, this impressive performance, while indicative of powerful algorithmic architecture, stems from training data that is a statistical reflection of public text, not a causal map of patient biology, disease progression, or treatment efficacy. These models are not inherently designed to understand the intricate, longitudinal relationships between interventions and real-world clinical outcomes. Their knowledge is derived from aggregated, often de-identified, and sometimes theoretical information, fundamentally different from the proprietary, granular, and ethically sourced patient data required for clinical decision support or diagnostic AI.

Defining the Bedrock: What Constitutes “Real Patient Outcomes Data”?

“Real patient outcomes data” is not merely any health-related data; it is a specific, multi-modal, and longitudinal asset. It encompasses a comprehensive collection of information directly derived from patient interactions within the healthcare system, meticulously tracked over time. This includes, but is not limited to:

• Clinical Data: Electronic Health Records (EHRs), imaging studies (e.g., CT, MRI, ECG), laboratory results, and physician notes.
• Patient-Reported Outcomes (PROs): Data collected directly from patients regarding their health status, symptoms, and quality of life.
• Intervention Data: Detailed records of treatments, medications, surgeries, and other medical procedures.
• Longitudinal Follow-up: Crucially, this data is collected over extended periods, allowing for the observation of disease progression, treatment response, and long-term sequelae.
• Proprietary Nature: Often, this data is collected directly by the company or through exclusive partnerships, creating a “data moat” that is difficult for competitors to replicate.

This type of data, often collected under stringent regulatory frameworks like HIPAA and adhering to standards like FDA GMLP, moves beyond statistical approximations found in public datasets to provide a ground truth of how diseases manifest and how interventions perform in diverse patient populations.

AI-Native Platforms: Built on the Bedrock of Outcomes

AI-native health companies distinguish themselves by building their core products, data pipelines, and business models from inception around this real patient outcomes data. Their AI models are not an add-on but the central intelligence, meticulously trained and validated on datasets that directly reflect clinical reality. Consider Hello Heart, an exemplar in the cardiac space. Its platform is trained on data from over 118,000 eligible adults, capturing their blood pressure readings, lifestyle choices, and ultimately, their cardiovascular outcomes. This proprietary dataset allows Hello Heart’s AI to develop personalized insights and interventions that are directly correlated with improved patient health, a claim validated by numerous published studies. Hello Heart clinical validation studies Similarly, HeartFlow has amassed an extraordinary dataset of over 650,000 patients worldwide, with its technology built from more than 200 million annotated CT angiography images. This rich, multi-modal data allows their AI to create a personalized 3D model of coronary arteries and simulate blood flow, aiding clinicians in diagnosing coronary artery disease without invasive procedures. This level of data integration and clinical validation is a testament to an AI-native approach. Tempus AI, founded by Eric Lefkofsky, takes this concept further by integrating real genomic, clinical, and outcomes data across vast patient cohorts. Their platform is designed to learn from every patient, providing oncologists with data-driven insights to personalize cancer treatment. This multi-omic, real-world data foundation, with over 500 petabytes of de-identified clinical and molecular data, allows Tempus to identify subtle patterns that are invisible to general AI models trained on public, less granular information. These companies embody the definition of an AI-native health platform: they are trained on real patient outcomes data, operate within defined clinical guardrails, and possess published evidence of efficacy.

The Data Moat: Clinical Efficacy and Regulatory Defensibility

The reliance on real patient outcomes data creates a significant “data moat” for AI-native health companies. As noted by individuals like Eric Topol, the quality and specificity of training data are paramount for AI systems operating in high-stakes environments like healthcare. This proprietary data advantage translates into several critical benefits:

1. Enhanced Clinical Efficacy: Models trained on real-world outcomes are more likely to accurately predict disease progression, identify at-risk patients, and recommend effective interventions because they have learned from actual biological and clinical responses, not just statistical correlations in public text.
2. Regulatory Compliance and Approval: Regulatory bodies like the FDA, particularly its Center for Devices and Radiological Health (CDRH), increasingly demand robust clinical evidence and real-world performance data for AI-driven medical devices. Recent guidance, including the August 2025 final guidance on Predetermined Change Control Plans (PCCPs) and the June 2026 draft guidance on total product lifecycle management, emphasizes these requirements. Companies with direct access to and expertise in managing such data are better positioned to navigate the 510(k) or De Novo classification pathways and achieve regulatory clearance. Adherence to GMLP principles is significantly facilitated by a structured approach to outcomes data. FDA AI/ML Medical Device Guidance
3. Competitive Advantage and Scalability: Building and maintaining such a comprehensive, longitudinal dataset is immensely resource-intensive and time-consuming. This barrier to entry makes it exceedingly difficult for new entrants or generalist AI companies to replicate the performance and trustworthiness of established AI-native platforms. Companies like iRhythm Technologies, with their extensive dataset from approximately 8 million patients in the United States and Europe, demonstrate how a data moat can underpin a robust competitive position.
4. Reduced Algorithmic Drift: By continuously integrating new real-world outcomes data, AI-native platforms can more effectively monitor and mitigate algorithmic drift, ensuring their models remain accurate and relevant as patient populations and clinical practices evolve.

The distinction is clear: general AI applied to health, while useful for information synthesis, lacks the proprietary, real-world patient outcomes data that is non-negotiable for clinical efficacy and regulatory approval. In conclusion, the core argument remains: while generalist AI models demonstrate impressive capabilities on public data, they lack the one non-negotiable asset for clinical efficacy and regulatory approval, proprietary, longitudinal, real-world patient outcomes data. The examples of Hello Heart, Tempus AI, and HeartFlow unequivocally prove this thesis, showcasing how platforms built from the ground up on this data possess a fundamental, defensible advantage. For investors and clinicians alike, understanding this data-centric reality is crucial. Future investment and clinical adoption in the AI health space will, and indeed must, gravitate towards those platforms that demonstrate a verifiable commitment to, and proven efficacy derived from, the bedrock of real patient outcomes.